Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Jefferies downgrades BP to 'hold', slashes price target

(Sharecast News) - Jefferies downgraded BP on Monday to 'hold' from 'buy' and slashed the price target to 390p from 550p. "As we lower our oil price outlook for 25/'26, we see BP's strategy facing increasing execution risk: the company may soon have to face the hard choice between delivering on the leverage reduction target or suspending the buyback and/or, reducing its upstream growth ambitions," the bank said.

Jefferies said its large-cap order of preference is Shell, then TotalEnergies, then BP.

The bank pointed out that BP has the highest leverage in the sector. In February, BP presented a "credible" plan to reduce net debt by $5-9bn and hybrid debts by around $4bn by 2027, Jefferies said.

"However, in the current macro conditions, we see this plan as increasingly at risk: at $65/bbl oil prices, bp will generate circa $8bn lower CFFO compared to its '25-27 plan.

"This leaves de-gearing almost entirely driven by the execution of the $20bn divestment plan, which we see as facing greater risks due to global economic uncertainty."

It noted that year to date, BP has underperformed its European peers by around 5%.

"However, NTM (next twelve months) earnings estimates have fallen by 9pcp more than for the sector (12%), resulting in a relative price-to-earnings re-rating: currently at 14x versus the sector at 11x (FY25)."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.